文献速递胸部肿瘤

巩固性局部消融治疗改善EGFR突变同步寡转移NSCLC一线TKI治疗患者生存

Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs.
PubMed 文献 · J Thorac Oncol · 2018-05-29

本研究纳入145例IV期EGFR突变寡转移(≤5个转移灶)NSCLC患者,均接受一线EGFR-TKI治疗,比较巩固性局部消融治疗(LAT)至全部寡转移灶、部分病灶及未行LAT的生存差异。结果显示全LAT组中位PFS和OS均显著优于部分LAT组和未LAT组,且原发灶、脑转移灶和肾上腺转移灶的巩固LAT均与OS改善相关。

要点

  • 全LAT组中位PFS 20.6个月、OS 40.9个月,均显著优于部分LAT和未LAT组。
  • 部分LAT与未LAT组间PFS和OS差异无统计学意义。
  • 原发灶、脑转移灶和肾上腺转移灶的巩固LAT均与OS显著改善相关。

核心结论

  • 对于EGFR突变寡转移NSCLC患者,一线EGFR-TKI治疗期间对全部转移灶进行巩固性LAT可显著改善PFS和OS。

研究设计与样本

  • 回顾性队列研究,纳入2010年10月至2016年5月共145例IV期EGFR突变NSCLC且诊断2个月内转移灶≤5个的患者,均接受一线EGFR-TKI治疗。

主要发现

  • 全LAT组(51例,35.2%)、部分LAT组(55例,37.9%)和未LAT组(39例,26.9%)的中位PFS分别为20.6、15.6和13.9个月(p < 0.001)。
  • 三组中位OS分别为40.9、34.1和30.8个月(p < 0.001),全LAT组与部分LAT组或未LAT组差异显著,部分LAT组与未LAT组差异不显著。
  • 原发灶巩固LAT组中位OS 40.5个月 vs 31.5个月(p < 0.001),脑转移灶LAT组38.2 vs 29.2个月(p = 0.002),肾上腺转移灶LAT组37.1 vs 29.2个月(p = 0.032)。
  • 放疗相关≥3级不良事件包括肺炎(7.7%)和食管炎(16.9%)。

临床怎么用

  • 对于EGFR突变寡转移NSCLC患者,一线TKI治疗期间可考虑对全部寡转移灶进行巩固性LAT以改善生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The aim of the current study was to investigate whether consolidative local ablative therapy (LAT) can improve the survival of patients with stage IV EGFR-mutant NSCLC who have oligometastatic disease treated with first-line EGFR-tyrosine kinase inhibitor (TKI) therapy. METHODS: Patients with stage IV EGFR-mutant NSCLC and no more than five metastases within 2 months of diagnosis were identified. All patients were treated with first-line EGFR-TKIs. Consolidative LAT included radiotherapy, surgery, or both. Overall survival (OS) and progression-free survival (PFS) were estimated by Kaplan-Meier curves. RESULTS: From October 2010 to May 2016, 145 patients were enrolled, including 51 (35.2%) who received consolidative LAT to all oligometastatic sites (all-LAT group), 55 (37.9%) who received consolidative LAT to either primary tumor or oligometastatic sites (part-LAT group), and 39 (26.9%) who did not receive any consolidative LAT (non-LAT group). The median PFS in all-LAT, part-LAT, and non-LAT groups were 20.6, 15.6, and 13.9 months, respectively (p < 0.001). The median OS in all-LAT, part-LAT, and non-LAT groups were 40.9, 34.1, and 30.8 months, respectively (p < 0.001). The difference was statistically significant between the all-LAT group and part-LAT or non-LAT group but was not between the part-LAT and non-LAT group. The median OS was significantly improved with consolidative LAT for primary tumor (40.5 versus 31.5 months, p < 0.001), brain metastases (38.2 versus 29.2 months, p = 0.002), and adrenal metastases (37.1 versus 29.2 months, p = 0.032). Adverse events (grade ≥ 3) due to radiotherapy included pneumonitis (7.7%) and esophagitis (16.9%). CONCLUSIONS: The current study showed that consolidative LAT to all metastatic sites was a feasible option for patients with EGFR-mutant oligometastatic NSCLC during first-line EGFR-TKI treatment, with significantly improved PFS and OS compared with consolidative LAT to partial sites or observation alone.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Xu Q, Zhou F, Liu H, et al. Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs. J Thorac Oncol. 2018. PMID: 29852232. doi:10.1016/j.jtho.2018.05.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。